ReadCoor, Inc., a Boston, MA-based provider of novel imaging platform of gene locations, completed $23m Series A financing.
The round was led by Decheng Capital with participation from Lilly Asia Ventures, Vivo Capital, and Hansjörg Wyss.
The company intends to use the funds to develop and commercialize its sequencing platform.
Led by CEO Shawn Marcell, ReadCoor has developed FISSEQ, a platform enabling integration of high throughput sequencing, morphometric analysis, cellular location and three dimensional spatial imaging to enable the understanding of the transcriptome, introducing new opportunities for diagnostic insights and delivering therapeutics for cancer, immuno-oncology, infectious diseases, neurological and neuromuscular diseases, brain function and cognitive disorders.
Invented by a team headed by Wyss Core Faculty member and ReadCoor co-founder George Church, FISSEQ is currently in use by a Wyss-led consortium mapping neuronal connectomics to discover the brain’s learning patterns and synaptic design, toward the goal of advancing neural-derived machine learning algorithms. The project is funded by IARPA (Intelligence Advanced Research Projects Activity).
The company has entered into a worldwide licensing agreement with Harvard’s Office of Technology Development, securing exclusive rights to FISSEQ technology.